MD Anderson Research Highlights for July 27, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Clinical advances include treating hematologic cancers with effective targeted therapies, circulating tumor DNA as a biomarker for recurrence with colorectal liver metastases, and using magnetic resonance imaging (MRI) to guide surgical decisions for patients...
MD Anderson named #1 in the nation for cancer care
The University of Texas MD Anderson Cancer Center today was named number one in the nation for cancer care in U.S. News & World Report...
MD Anderson and Obsidian Therapeutics announce FDA clearance of IND application for novel TIL therapy OBX-115
The University of Texas MD Anderson Cancer Center and Obsidian Therapeutics, Inc. today announced Food and Drug Administration (...
Donna Hansel, M.D., Ph.D., to join MD Anderson as Division Head of Pathology and Laboratory Medicine
The University of Texas MD Anderson Cancer Center today announced that Donna Hansel, M.D., Ph.D., has been named Division Head of Pathology and Laboratory Medicine. A distinguished pathologist, researcher and leader, Hansel will join MD Anderson Sept. 12.
Hansel will lead a team of 650, including more than 130 clinical and research faculty, across four departments that serve as a bridge between basic research, translational research...
Kimberly Hoggatt Krumwiede, Ph.D., named Dean of MD Anderson’s School of Health Professions
The University of Texas MD Anderson Cancer Center today announced Kimberly Hoggatt Krumwiede, Ph.D., as dean of MD Anderson’s School of Health...